| Schedule of Cash, Cash Equivalents, Restricted Cash and Marketable Securities |
The following tables summarize the Company’s
cash, cash equivalents, restricted cash and marketable securities as of March 31, 2025 and December 31, 2024.
Schedule of Cash, Cash Equivalents, Restricted
Cash and Marketable Securities
| As of March 31, 2025 | |
| | |
| | |
| | |
| |
| | |
Amortized Cost | | |
Unrealized Gain | | |
Unrealized (Loss) | | |
Fair Value | |
| Cash, cash equivalents and restricted cash | |
$ | 4,027 | | |
$ | — | | |
$ | — | | |
$ | 4,027 | |
| | |
| | | |
| | | |
| | | |
| | |
| Marketable Securities: | |
| | | |
| | | |
| | | |
| | |
| U.S. Treasury Bills | |
| 3,982 | | |
| — | | |
| — | | |
| 3,982 | |
| Total marketable securities | |
| 3,982 | | |
| — | | |
| — | | |
| 3,982 | |
| | |
| | | |
| | | |
| | | |
| | |
| Total cash, cash equivalents, restricted cash and marketable securities | |
$ | 8,009 | | |
$ | — | | |
$ | — | | |
$ | 8,009 | |
| | |
| | | |
| | | |
| | | |
| | |
| As of December 31, 2024 | |
| | | |
| | | |
| | | |
| | |
| | |
| Amortized Cost | | |
| Unrealized
Gain | | |
| Unrealized
(Loss) | | |
| Fair Value | |
| Cash, cash equivalents and restricted cash | |
$ | 3,700 | | |
$ | — | | |
$ | — | | |
$ | 3,700 | |
| | |
| | | |
| | | |
| | | |
| | |
| Marketable Securities: | |
| | | |
| | | |
| | | |
| | |
| U.S. Treasury Bills | |
| 8,519 | | |
| — | | |
| — | | |
| 8,519 | |
| Total marketable securities | |
| 8,519 | | |
| — | | |
| — | | |
| 8,519 | |
| | |
| | | |
| | | |
| | | |
| | |
| Total cash, cash equivalents, restricted cash and marketable securities | |
$ | 12,219 | | |
$ | — | | |
$ | — | | |
$ | 12,219 | |
|